Human Transmembrane glycoprotein NMB(GPNMB) ELISA kit

Product Details

Customer Reviews and Q&A

Target Background

Home
Product
Kit
ELISA Kits
Human Transmembrane glycoprotein NMB(GPNMB) ELISA kit

Name: Human Transmembrane glycoprotein NMB(GPNMB) ELISA kit
Brand: CUSABIO
SKU: CSB-EL009727HU-IS

Promotion

Code: CSB-EL009727HU-IS

Rate （N/A）
Review （0）

Size:

96T,5×96T,10×96T

Pls inquire

Quantity:

Sample Types: serum, plasma, tissue homogenates, cell culture supernates

Detect Range: 0.156 ng/mL-10 ng/mL

Sensitivity: 0.039 ng/mL

Trial Size:

24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >>

Interested in a trial size? Please leave a message below.

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Promotion

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Alternative Names

Glycoprotein (transmembrane) nmb ELISA Kit; Glycoprotein nmb ELISA Kit; Glycoprotein nmb like protein ELISA Kit; Gpnmb ELISA Kit; GPNMB_HUMAN ELISA Kit; HGFIN ELISA Kit; NMB ELISA Kit; Osteoactivin ELISA Kit; Transmembrane glycoprotein ELISA Kit; Transmembrane glycoprotein HGFIN ELISA Kit; Transmembrane glycoprotein NMB ELISA Kit

Abbreviation

GPNMB

Uniprot NO.

Q14956

Species

Homo sapiens (Human)

Sample Type

serum, plasma, tissue homogenates, cell culture supernates

Detection Range

0.156 ng/mL-10 ng/mL

Sensitivity

0.039 ng/mL

Assay Time

1-5h

Sample Loading Volume

50-100ul

Detection Wavelength

450 nm

Research Area

Cancer

Assay Principle

quantitative
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.

Measurement

Sandwich

Storage

Store at 2-8°C. Please refer to protocol.

Shelf Life

6 months

Lead Time

3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Precision

Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of human GPNMB in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

	Sample	Serum(n=4)
1:1	Average %	95
	Range %	88-101
1:2	Average %	101
	Range %	94-107
1:4	Average %	98
	Range %	92-105
1:8	Average %	92
	Range %	85-98

Recovery

Typical Data

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

ng/ml

OD1

OD2

Average

Corrected

2.719

2.634

2.677

2.514

2.069

1.947

2.008

1.846

2.5

1.275

1.228

1.252

1.090

1.25

0.743

0.729

0.736

0.574

0.625

0.519

0.521

0.520

0.358

0.312

0.349

0.333

0.341

0.179

0.156

0.239

0.244

0.242

0.080

0.164

0.160

0.162

Protocols

/uploadfile/Ins/CSB-EL009727HU-IS.pdf

Troubleshooting and FAQs

ELISA kit FAQs

ELISA Data Analysis

ELISA Standard Curve & Curve Expert software

Description

This ELISA kit provides quantitative measurement of glycoprotein nonmetastatic melanoma protein B (GPNMB) in human samples, supporting oncology research where GPNMB drives tumor progression, immune evasion, and metastasis. Because GPNMB is both a shed extracellular domain circulating in blood and an overexpressed protein within the tumor microenvironment, researchers need an assay that performs across both fluid and solid tissue contexts.

Detection Range: The 0.156–10 ng/mL range aligns with reported circulating soluble GPNMB levels, which are elevated in patients with breast cancer, glioblastoma, and melanoma compared to healthy controls. Most serum and plasma samples can be measured directly or with minimal dilution, while concentrated tissue homogenates may require titration to fall within range.

Sensitivity: At 0.039 ng/mL, the kit detects GPNMB in low-abundance conditions such as early-stage tumor conditioned media or plasma from patients prior to significant disease burden, where shed ectodomain concentrations remain near baseline.

Sample Compatibility: Validation across serum, plasma, tissue homogenates, and cell culture supernatants enables paired analyses — comparing circulating soluble GPNMB with intratumoral expression or in vitro shedding from cancer cell lines treated with metalloproteinase inhibitors.

Assay Efficiency: The 1–5 hour protocol using 50–100 µL accommodates limited clinical biopsy-derived homogenates and small-volume conditioned media harvests from primary tumor cultures.

This kit directly supports studies in antibody-drug conjugate biomarker stratification, melanoma progression monitoring, and tumor immune microenvironment profiling.

■ Customer Reviews

Submit a Review here

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

Function(From Uniprot)

Could be a melanogenic enzyme.

Gene References into Functions

loss of GPNMB, which has been implicated in melanosome formation, autophagy, phagocytosis, tissue repair, and negative regulation of inflammation, underlies autosomal-recessive Amyloidosis cutis dyschromica. PMID:29336782
Study shows high GPNMB mRNA level in osteosarcoma tissues and cell lines. Its silencing regulates the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/Akt/mTOR signaling pathway. PMID:29620278
Serum levels of GPNMB were highly correlated with accumulation of bioactive lipid substrate of Gaucher disease, glucosylsphingosine as well as established biomarkers, chitotriosidase and chemokine, CCL18. PMID:28003098
Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease PMID:28391543
This study revealed that GPNMB aggregates are localized to the neuron, and not localized to the astrocyte and microglia and in the spinal cord of ALS patients. GPNMB has protective effects against mutant TDP-43-induced motor neuron cell death, via ERK1/2 and Akt pathway.. PMID:27935101
This review will summarize the latest understanding of Gpnmb in the aspects of diagnosis, progression and prognosis of pathological disorders and neoplasms, emphasizing the clinical advances in targeting Gpnmb-expressing malignancies--{REVIEW} PMID:29441921
The combination of MAPK pathway inhibitors with an antibody-drug conjugate targeting GPNMB is an effective therapeutic option. PMID:27515299
High GPNMB expression is associated with enhancement of invasive behavior in lung cancer. PMID:26883195
Findings suggest that MAFK and its target gene GPNMB play important roles in the malignant progression of triple-negative breast cancer (TNBC) cells, offering potentially new therapeutic targets for TNBC patients. PMID:28400538
glycoprotein non-metastatic B presented increased expression in breast cancer in vivo compared to normal breast tissue PMID:28689015
Osteoactivin differential regulates the expression of matrix metalloproteases in head and neck squamous cell carcinomas to promote cancer cell invasion. PMID:28295306
The GPNMB is expressed in a temporal manner during eosinophil development and delivers a proliferative signal upon activation. PMID:28104809
it may be premature to conclude associations between GPNMB rs156429 and Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. PMID:27132081
Glycoprotein nonmetastatic melanoma protein B protein was highly expressed in the bladder cancer, which was related to the poor prognosis in bladder cancer patients. Glycoprotein nonmetastatic melanoma protein B promoted the proliferation, migration, and invasion in bladder cancer cells. PMID:28443476
an inducer for glioma and could enhance matrix metalloproteinase activity through Wnt/beta-catenin pathway to contribute to glioma tumorigenesis PMID:27334625
findings indicate that GPNMB promotes glioma growth via Na(+)/K(+)-ATPase alpha subunits. Thus, the interaction between GPNMB and Na(+), K(+)-ATPase alpha subunits represents a novel therapeutic target for the treatment of brain glioblastomas. PMID:27836549
Finally, we identify glycoprotein NMB as a melanocytic marker up-regulated in Tsc2-null mouse uteri and human lymphangioleiomyomatosis samples PMID:26880751
The GPNMB is a promising biomarker and therapeutic target for the development and progression of Nonalcoholic fatty liver disease in obesity. PMID:26581806
Osteoactivin in the extracellular matrix promotes oral squamous carcinoma cell adhesion and migration. PMID:26636434
Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease PMID:26771826
GPNMB might be a surrogate marker for BC and may cross talk with the HER2 signal pathway. PMID:26077887
GPNMB plays an important roles in regulating the expression of key pluripotency genes in dental pulp cells and modifying odontogenic differentiation. PMID:26261527
A positive correlation between GPNMB and NRP-1 levels in human breast tumors. PMID:25772243
Data shows that the expression of Gpnmb and Spp1 is highly upregulated in glioma-associated microglia/macrophages highlighting the importance of macrophages and microglia as therapeutic targets in anti-tumor treatment regimens. PMID:25658639
GPNMB/OA protein expression prevents cells from apoptosis-enhancing proliferation and represents a novel modulator of the invasion and metastasis in pancreatic cancer cells. PMID:25426614
The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. PMID:25889792
GPNMB mRNA in FLCN-related renal cell carcinomas was 23-fold more abundant than in sporadic tumors. PMID:25594584
GPNMB has protective effect against ischemia-reperfusion injury via phosphorylation of ERK1/2 and Akt PMID:25010402
Glycoprotein nonmetastatic melanoma protein B plays an important role in angiogenesis during hyperoxia injury PMID:25054912
DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma PMID:24933321
Our data identify Gpnmb as a novel marker for obesity-induced adipose tissue macrophage infiltration and potentiator of interleukin-4 responses and point toward a crucial role for MITF in driving part of the adipose tissue macrophage phenotype. PMID:24789918
GPNMB/OA acts as a critical molecular mediator promoting the acquisition of the more aggressive, pro-metastatic phenotype distinctive of human DU145 and PC3 cell lines. PMID:24589892
our findings will clarify a new explanation about how GPNMB induces bone repair, and provide a potential target for bone regeneration therapeutics and bone engineering PMID:23794283
the molecular basis for the distinct trafficking and morphogenetic properties of PMEL and GPNMB is the PKD domain PMID:23452376
GPNMB expression was regulated by EpCAM and CSF-1 partly through their common downstream product c-myc PMID:23924854
Silencing of GPNMB by siRNA inhibits the formation of melanosomes in melanocytes in a MITF-independent fashion. PMID:22912767
GPNMB inhibits motor neuron death and plays a critical role in motor neuron survival. PMID:22891158
Together these results suggest that GPNMB gene is a p53- and androgen-dysregulated gene and should be regarded as an anti-tumor gene for prostate cancer. PMID:22290289
The abnormal expression of GPNMB may play an important role in the development of prostate cancer. PMID:21844952
Gastrointestinal stromal tumours do not show immunopositivity for ERa or HMB45. PMID:22014058
upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors PMID:21874302
GPNMB increase in kidney disease was confirmed by real-time PCR after 5/6 nephrectomy, in streptozotocin-induced diabetes, and in patients with chronic kidney disease PMID:21389974
Toxin-conjugated DC-HIL to abrogate the ability of Sezary syndrome cells to proliferate in vitro. PMID:21252093
ADAM10 as a sheddase capable of releasing the GPNMB/OA ectodomain from the surface of breast cancer cells PMID:20711474
GPNMB expression has a role in uveal melanoma PMID:20375921
GPNMB expression is associated with the basal/triple-negative subtype and is a prognostic marker of poor outcome in patients with breast cancer. PMID:20215530
GPNMB is a melanosomal protein that is released by proteolytic ectodomain shedding and might be a useful and specific histological marker of melanocytic cells. PMID:20056711
Human OA uses the same transcriptional initiation site in both bone and kidney as was reported for melanoma cells and is expressed in osteoblast cultures at all stages of differentiation PMID:14696968
cloning and analysis of two fragments in the 5' flanking region of HGFIN; studies indicate p53 cooperates with cytokine-mediated transcription factors to regulate the expression of HGFIN PMID:15684612
Osteoactivin is expressed at high levels in normal and inflammatory liver macrophages suggesting a significant role in acute liver injury. PMID:15763343

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein. Melanosome membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein.

Protein Families

PMEL/NMB family

Tissue Specificity

Widely expressed, but very low expression, if any, in the brain. Expressed in the epidermis with higher levels in melanocytes compared with keratinocytes and Langerhans cells (at protein level). Expressed in peripheral blood, but not bone marrow mononucle

Database Links

HGNC: 4462

UNIGENE: Hs.190495

KEGG: hsa:10457

STRING: 9606.ENSP00000371420

OMIM: 604368

Promotions